Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Sunrise Air, an FDA-cleared rechargeable home sleep testing device, enables multi-night monitoring of sleep apnea using a minimalist chin sensor rather than traditional clinic-based polysomnography. This approach addresses both the practical barriers to diagnosis and the physiological reality that sleep patterns vary significantly night-to-night, making single-night clinical studies insufficient for accurate apnea detection.
Sunrise Air, an FDA-cleared at-home sleep test that monitors mandibular jaw movement alongside respiratory sensors, enables multi-night testing without disposable components. The device applies AI algorithms to distinguish obstructive from central apneas, addressing diagnostic complexity in a condition affecting over 900 million people globally.
Insilico Medicine has advanced Rentosertib, an AI-designed TNIK inhibitor, into Phase 1 human trials for pulmonary fibrosis after demonstrating improved lung function and reduced fibrosis markers in preclinical studies. This represents a significant milestone for AI-driven drug discovery, with implications for accelerating therapeutic development in progressive fibrotic conditions.
HCW11-040, a pembrolizumab-derived immunotherapeutic, prevented bronchopulmonary dysplasia in preclinical models by eliminating oxygen-induced senescent cells and restoring exhausted immune function. This represents a potential first-in-class intervention for a rare pediatric lung disease affecting 10,000–15,000 U.S. infants annually, with IND filing anticipated in late 2027.
Moderate hyperoxia induces cellular senescence in developing airway tissue, with lasting consequences for lung function. Three mechanistically distinct interventions—Fucoidan, Dasatinib plus Quercetin, and MitoQ—each mitigate senescence through different pathways, offering potential strategies to prevent hyperoxia-related lung disease in premature infants.
Fine particulate matter (PM2.5) exposure drives cognitive decline and dementia incidence, with burden increasing substantially as populations age. Understanding how demographic shifts amplify PM2.5-related dementia risk across aging cohorts is essential for longevity strategy in rapidly aging societies.
Insilico Medicine obtained investigational new drug clearance for an inhaled formulation of rentosertib, a TNIK inhibitor discovered through AI-driven drug discovery, designed to deliver targeted lung exposure in idiopathic pulmonary fibrosis. The inhalation route enables higher local bioavailability at lower systemic doses, advancing a potential therapeutic for a progressive fibrotic lung condition.
The Super Age Games reframe competitive fitness around healthspan—the quality and sustainability of functional life—rather than isolated performance metrics. This shifts how populations measure aging success, integrating physical, cognitive, metabolic, and social dimensions into a single assessment model that reflects real-world health integration.
Calluna Pharma has completed enrollment in a Phase 2 trial of CAL101, a monoclonal antibody targeting S100A4 to preserve lung function in idiopathic pulmonary fibrosis, a disease with median survival of 3-5 years. Topline results are expected in Q1 2027.
Respiratory function declines with age through both structural changes and molecular factors, but understanding how normal aging manifests in the lungs creates opportunity for targeted interventions. This framework shifts focus from treating late-stage disease to addressing the upstream mechanisms that accelerate pulmonary decline.
The rejuvenation research field is advancing through improved diagnostic technology, clinical trial progress, and coordinated business-advocacy efforts. Non-invasive voice and gait biomarkers show promise for early detection of age-related diseases, particularly neurodegenerative conditions and infectious diseases, while the field strengthens its capacity to move discoveries into clinical application.
Life Time's nationwide rollout of SpiroFit metabolic testing brings laboratory-grade VO₂ max and fuel-utilization data into mainstream fitness clubs, enabling members to identify metabolic inflection points and train with precision rather than assumption. This democratization of metabolic testing shifts a central longevity marker—previously available only to elite athletes—into accessible measurement for the general population.